NEW YORK - Shares of Barr Pharmaceuticals Inc. plunged Thursday after the drug developer reported first-quarter profit below Wall Street expectations and slashed its 2008 forecast, leading at least one analyst to downgrade the stock.
| BRL | 66.75 |
The stock fell $11.65, or 23.5 percent, to $38 in afternoon trading. Shares hit their lowest point in more than three years earlier in the trading session, falling to $37.40.
"Given challenges, we think recovery could take time with multiple headwinds emerging from the first quarter," said Goldman Sachs analyst Randall Stanicky, downgrading the stock to "Neutral" from "Buy".
In a note to investors, Stanicky said the lower guidance appears to be influenced by a mix of weak U.S. generic sales, lower sales of contraceptives, and higher research and development costs.
Earlier in the day, the Montvale, N.J.-based company reported its first-quarter profit doubled, but generic contraceptive sales declined. Overall results missed Wall Street forecasts.
The decline in contraceptive sales prompted the company to reduce its full-year guidance to a range of $2.75 to $3.05 per share, from a previous forecast of $3.05 to $3.35 per share. The company forecast revenue between $2.7 billion and $2.8 billion.
Analysts polled by Thomson Financial forecast earnings of $3.27 per share on revenue of $2.78 billion.

At first I was going to post this story from the UK Telegraph as an interesting piece... food for thought if you will... with the tag that this t...


Online distributor for point of sale equipment, TYSSO and Pegasus.